BioNTech, una dintre companiile care a dezvoltat un vaccin anti-COVID, ar putea închide trei fabrici din Germania

BioNTech plans to close three factories in Germany, risking 1,800 jobs due to overcapacity and cost-cutting measures. The company aims to save up to 500 million euros annually to invest in cancer drug development. If no buyer is found, the facilities in Idar-Oberstein, Marburg, and Tübingen will shut down. Despite significant earnings from COVID-19 vaccines, BioNTech has struggled to launch new products. The company also announced a new CEO, Guido Oelkers, set to take over by February 2027, as co-founder Ugur Sahin prepares to leave for a new venture focused on mRNA technology. BioNTech reported a billion-euro loss last year, anticipating reduced vaccine sales going forward.